|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84,000 KRW | -0.24% |
|
+2.94% | -16.33% |
| Jan. 30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
| 2023 | SK Group Advances Net Zero Transition via Key Renewable Energy Deal | MT |
Cala Health, Inc. announced that it will issue 33,413,525 series D preferred shares at issue price of $1.4964 per share for the gross proceeds $49,999,998.81 in funding on November 4, 2021. The shares are convertible, participating and non-cumulative. The shares carry non-cumulative dividend value of $0.12 per annum per share.
The shares will be convertible in common shares at a price of $1.4964 per share. The company will issue securities pursuant to exemption provided under Regulation D.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.33% | 4.79B | |
| +11.94% | 9.18B | |
| +6.40% | 3.97B | |
| +26.98% | 3.98B | |
| +27.59% | 2.56B | |
| -26.55% | 2.29B | |
| -25.02% | 2.23B | |
| +5.82% | 1.92B | |
| -0.50% | 1.64B | |
| +3.49% | 1.64B |
SK BIOPHARMACEUTICALS CO., LTD. 
